Full Press Release Details
Immutep Granted Japanese Patent for Eftilagimod Alpha, a Soluble Lag-3 Protein, in Combination with a PD-1 Pathway Inhibitor.
IMMP
Immutep Granted Japanese Patent for Eftilagimod Alpha, a Soluble Lag-3 Protein, in Combination with a PD-1 Pathway Inhibitor
Key Takeaway: Immutep Granted Japanese Patent for Eftilagimod Alpha, a Soluble Lag-3 Protein, in Combination with a PD-1 Pathway Inhibitor
Price reaction · baseline $2.02 (2022-08-26 close) · 2 other IMMP headline(s) in the window, move may be shared
day 0 close
-1%
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+76%
120-day peak, hindsight
Typical move
5.4%
average across 13 past catalysts
Lead asset
eftilagimod alfa
Phase 3 · Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)